{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:01:29Z","timestamp":1792022489694,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>WHO strategy to end Tuberculosis (TB) calls for drug susceptibility testing of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB) for all patients, in high TB burden settings. Thus, this study aimed to investigate the MTB drug resistance profiles and related risk factors among patients presenting to the Antituberculosis Center of Brazzaville, Republic of Congo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cross-sectional study was carried out from July 2022 to August 2023 involving 1,121 presumptive pulmonary tuberculosis patients enrolled to the Antituberculosis Center of Brazzaville. Sputum samples were collected from all the study participants for the diagnosis of tuberculosis and rifampicin resistance, using the Xpert MTB\/RIF (Cepheid, USA) assay. Samples positive for MTB with drug resistance to RIF were further tested for the second line anti-MTB drug susceptibility using the 10-color Xpert MTB\/XDR assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result<\/jats:title>\n            <jats:p>Out of 1,121 presumptive TB patients tested, 302\/1,121 (26.9%) were MTB positive. Among these, 18\/302 (6.0%) had received previous TB treatment and 15\/302 (5.0%) were HIV co-infected. The mean age of the study population was 34 years, with a higher prevalence in males (69.2%). Of the MTB isolates, 25\/302 (8.3%) were Rifampicin-resistant, with 24\/25 (96%) further confirmed as multi-resistant strains, including 6\/24 (25%) pre-XDR. Risk factors for MDR-TB included a history of TB treatment (AOR\u2009=\u20098.96, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) and chronic cough (AOR\u2009=\u20097.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study reveals a high level of drug-resistant tuberculosis in Brazzaville, with previous TB treatment being a significant risk factor. The findings underscore the need to strengthen molecular surveillance and TB management and control measures in the Republic of Congo.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12941-025-00786-8","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:34:27Z","timestamp":1746801267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo"],"prefix":"10.1186","volume":"24","author":[{"given":"Breli Bonheur","family":"Ngouama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Djontu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel Ornelle","family":"Elion Assiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freisnel Hermeland","family":"Mouzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita Naomie Merveille","family":"Dello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabar Babatunde Pacome Agbo Achimi","family":"Abdul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Mebiame","family":"Biyogho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett Chester","family":"Mevyann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy Arnault Rogue","family":"Mfoumbi Ibinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheska Epola","family":"Dibamba Ndanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck Hardain","family":"Okemba Okombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Illoye","family":"Ayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemercier Khunell","family":"Siele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ro\u00e9lie Foxie","family":"Mizele Kitoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannhey Christevy","family":"Vouvoungui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain Maxime","family":"Mouanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain Brice","family":"Vouidibio Mbozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Penlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayola Akim","family":"Adegnika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Peter","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Ntoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"786_CR1","unstructured":"World Health Organization. Global Tuberculosis Report WHO Geneva. 2024."},{"issue":"3","key":"786_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/trstmh\/trv108","volume":"110","author":"K L\u00f6nnroth","year":"2016","unstructured":"L\u00f6nnroth K, Raviglione M. The who\u2019s new end TB strategy in the post-2015 era of the sustainable development goals. Trans R Soc Trop Med Hyg. 2016;110(3):148\u201350.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"786_CR3","unstructured":"World Health Organization. Global Tuberculosis Report. WHO Geneva. 2015."},{"issue":"1","key":"786_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-016-2151-5","volume":"17","author":"P Ding","year":"2017","unstructured":"Ding P, et al. Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. BMC Infect Dis. 2017;17(1):57.","journal-title":"BMC Infect Dis"},{"key":"786_CR5","unstructured":"World Health Organization. Global Tuberculosis Report. WHO Geneva. 2020."},{"key":"786_CR6","unstructured":"Meeting report of the WHO expert consultation on the definition of extensively Drug-Resistant tuberculosis. 2020;27\u201329(1). 1st ed. Geneva: World Health Organ. 2021. p."},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.2147\/IDR.S335329","volume":"14","author":"J Lecai","year":"2021","unstructured":"Lecai J, et al. Predictors and trends of MDR\/RR-TB in Shenzhen China: A retrospective 2012\u20132020 period analysis. Infect Drug Resist. 2021;14:4481\u201391.","journal-title":"Infect Drug Resist"},{"key":"786_CR8","unstructured":"World Health Organization. Global Tuberculosis Report. WHO Geneva. 2019."},{"issue":"3","key":"786_CR9","first-page":"289","volume":"28","author":"FH Okemba Okombi","year":"2018","unstructured":"Okemba Okombi FH, et al. Extensively resistant tuberculosis: four cases in the Republic of congo. Med Sante Trop. 2018;28(3):289\u201391.","journal-title":"Med Sante Trop"},{"key":"786_CR10","unstructured":"Programme National De Lutte Contre La Tuberculose (PNLT). Rapport Technique. 2023."},{"key":"786_CR11","unstructured":"World Health Organization. Global Tuberculosis Report. WHO Geneva. 2023."},{"key":"786_CR12","unstructured":"World Health Organization. Global Tuberculosis Report. WHO Geneva. 2022."},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1186\/s13104-015-1774-8","volume":"8","author":"LS Linguissi","year":"2015","unstructured":"Linguissi LS, et al. Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. BMC Res Notes. 2015;8:804.","journal-title":"BMC Res Notes"},{"issue":"3","key":"786_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3201\/eid2303.160679","volume":"23","author":"S Malm","year":"2017","unstructured":"Malm S, et al. New Mycobacterium tuberculosis complex sublineage, Brazzaville, congo. Emerg Infect Dis. 2017;23(3):423\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"786_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12941-021-00488-x","volume":"20","author":"DO Elion Assiana","year":"2021","unstructured":"Elion Assiana DO, et al. Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium tubrculosis among Congolese patients. Ann Clin Microbiol Antimicrob. 2021;20(1):84.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"786_CR16","doi-asserted-by":"crossref","unstructured":"Cao Y et al. Xpert MTB\/XDR: a 10-Color reflex assay suitable for Point-of-Care settings to detect Isoniazid, fluoroquinolone, and Second-Line-Injectable-Drug resistance directly from Mycobacterium tuberculosis-Positive sputum. J Clin Microbiol. 2021;59(3).","DOI":"10.1128\/JCM.02314-20"},{"key":"786_CR17","unstructured":"Okemba-Okombi F, Kaswa Kayomo M, Bopaka R. Ndinga Essango E, Kaswa Kayomo M, Ossale Abacka B, Bopaka R, Atipo Ibara B. Multi-resistant tuberculosis in Brazzaville: Epidemiological, clinical, radiographic and progressive aspects. J Funct Vent Pulmonol. 2020;11(33). Available from: https:\/\/www.jfvpulm.com\/Post\/showPost\/491"},{"issue":"11","key":"786_CR18","doi-asserted-by":"publisher","first-page":"e13901","DOI":"10.1371\/journal.pone.0013901","volume":"5","author":"HS Cox","year":"2010","unstructured":"Cox HS, et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS ONE. 2010;5(11):e13901.","journal-title":"PLoS ONE"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12889-016-3210-y","volume":"16","author":"SD Hamusse","year":"2016","unstructured":"Hamusse SD, et al. Primary and secondary anti-tuberculosis drug resistance in Hitossa district of Arsi zone, oromia regional State, central Ethiopia. BMC Public Health. 2016;16:593.","journal-title":"BMC Public Health"},{"key":"786_CR20","doi-asserted-by":"crossref","unstructured":"Monde N et al. First and Second-Line Anti-Tuberculosis Drug-Resistance patterns in pulmonary tuberculosis patients in Zambia. Antibiot (Basel). 2023;12(1).","DOI":"10.3390\/antibiotics12010166"},{"issue":"6","key":"786_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.5588\/ijtld.14.0785","volume":"19","author":"NV Nhung","year":"2015","unstructured":"Nhung NV, et al. The fourth National anti-tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015;19(6):670\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"786_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3201\/eid2703.203204","volume":"27","author":"SV Leavitt","year":"2021","unstructured":"Leavitt SV, et al. Decentralized care for Rifampin-Resistant tuberculosis, Western cape, South Africa. Emerg Infect Dis. 2021;27(3):728\u201339.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"786_CR23","first-page":"e5541","volume":"11","author":"M Sharma","year":"2019","unstructured":"Sharma M, et al. Determinants of drug resistance in Previously-Treated pulmonary tuberculosis patients registered at a chest clinic in South Delhi, India. Cureus. 2019;11(8):e5541.","journal-title":"Cureus"},{"issue":"1","key":"786_CR24","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41598-023-29804-5","volume":"13","author":"AM Fofana","year":"2023","unstructured":"Fofana AM, et al. Cross-municipality migration and spread of tuberculosis in South Africa. Sci Rep. 2023;13(1):2674.","journal-title":"Sci Rep"},{"issue":"1","key":"786_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12879-020-05749-2","volume":"21","author":"ZZ Sultana","year":"2021","unstructured":"Sultana ZZ, et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):51.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"786_CR26","first-page":"333","volume":"31","author":"B Pourakbari","year":"2019","unstructured":"Pourakbari B, et al. Prevalence of TB\/ HIV co-infection in Iran: a systematic review and meta-analysis. Ann Ig. 2019;31(4):333\u201348.","journal-title":"Ann Ig"},{"issue":"1","key":"786_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12879-017-2345-5","volume":"17","author":"P Chanda-Kapata","year":"2017","unstructured":"Chanda-Kapata P, et al. The prevalence of HIV among adults with pulmonary TB at a population level in Zambia. BMC Infect Dis. 2017;17(1):236.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"786_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.4314\/ahs.v21i3.7","volume":"21","author":"MA Zeru","year":"2021","unstructured":"Zeru MA. Prevalence and associated factors of HIV-TB co-infection among HIV patients: a retrospective study. Afr Health Sci. 2021;21(3):1003\u20139.","journal-title":"Afr Health Sci"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/1756-0500-7-578","volume":"7","author":"LS Linguissi","year":"2014","unstructured":"Linguissi LS, et al. Prevalence of National treatment algorithm defined smear positive pulmonary tuberculosis in HIV positive patients in Brazzaville, Republic of Congo. BMC Res Notes. 2014;7:578.","journal-title":"BMC Res Notes"},{"issue":"6","key":"786_CR30","doi-asserted-by":"publisher","first-page":"e044349","DOI":"10.1136\/bmjopen-2020-044349","volume":"11","author":"NN Tao","year":"2021","unstructured":"Tao NN, et al. Risk factors for drug-resistant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China, during 2004\u20132019. BMJ Open. 2021;11(6):e044349.","journal-title":"BMJ Open"},{"key":"786_CR31","doi-asserted-by":"publisher","first-page":"820134","DOI":"10.3389\/fimmu.2022.820134","volume":"13","author":"MR Cronan","year":"2022","unstructured":"Cronan MR. In the Thick of it: formation of the tuberculous granuloma and its effects on host and therapeutic responses. Front Immunol. 2022;13:820134.","journal-title":"Front Immunol"},{"key":"786_CR32","doi-asserted-by":"crossref","unstructured":"Silva Miranda M et al. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria? Clin Dev Immunol. 2012;139127.","DOI":"10.1155\/2012\/139127"},{"key":"786_CR33","unstructured":"Programme National De Lutte Contre La Tuberculose (PNLT). Rapport Technique 2016."}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-025-00786-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-025-00786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:34:33Z","timestamp":1746801273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-025-00786-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1186\/s12941-025-00786-8","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethical clearance was obtained from the ethics committee of the Fondation Congolaise pour la Recherche M\u00e9dicale after the review of the protocol. Prior to enrolment, participants were informed about the purpose of the study and written informed consent was obtained from each recruited participant. For participants between 8 and 17 years old, assent was obtained from the individuals and signed informed consent was obtained from parents or guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potential conflicts of interest"}}],"article-number":"31"}}